that was similar to daily shots of Lantus and Tresiba. The safety and tolerability profile of efsitora was in line with those of the daily basal insulin therapies. These above results are also ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Toujeo (insulin glargine [rDNA origin]) has ... found blood sugar control with Toujeo was comparable to Lantus, with an improved safety profile. The incidence of confirmed hypoglycaemia was ...